EraGen Biosciences to have access to Illumina’s BeadXpress platform

EraGen Biosciences Inc., a developer of novel molecular reagents for the in-vitro diagnostics (IVD) market, and Illumina Inc., a global company that develops, manufactures and markets integrated systems for analysis of genetic variation and biological function, today announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements.

Under these licensing agreements, EraGen Biosciences will have access to Illumina’s BeadXpress platform for the continued development and commercialization of molecular-based, high-throughput clinical multiplexed assays with its unique, patented MultiCode®-PLx technology. EraGen has proven commercial success with multiplex molecular assays for the infectious disease and genetic disorder markets. Illumina has licensed EraGen’s MultiCode-PLx technology for the life sciences, research and clinical markets.

“We are very excited by the opportunities this partnership presents to EraGen. Our newly formed relationship with Illumina further validates our MultiCode technology’s versatile application in the development and commercialization of molecular-based assays for the clinical market,” stated Irene Hrusovsky, M.D., President and CEO of EraGen Biosciences Inc.

“We look forward to seeing the delivery of innovative solutions through the combination of Illumina and EraGen technologies,” said Greg Heath, Senior Vice President and GM of Illumina’s diagnostic division. “We view this agreement as a first step toward advancing healthcare through leading-edge molecular tools.”

This partnership is part of EraGen’s strategy to continue to expand its commercial efforts in the molecular diagnostics market.

“We will continue to bring to market innovative, high-value molecular diagnostic tests and solutions through strategic platform partnerships and the advancement of a broad product pipeline that is responsive to our customers’ needs,” added Dr. Hrusovsky.

EraGen’s goal is to provide its customers in the molecular diagnostics laboratory with an integrated solution that provides rapid, reliable results for improving the clinical management of patients.

 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2019, June 18). EraGen Biosciences to have access to Illumina’s BeadXpress platform. News-Medical. Retrieved on April 01, 2020 from https://www.news-medical.net/news/20091123/EraGen-Biosciences-to-have-access-to-Illuminae28099s-BeadXpress-platform.aspx.

  • MLA

    Illumina, Inc.. "EraGen Biosciences to have access to Illumina’s BeadXpress platform". News-Medical. 01 April 2020. <https://www.news-medical.net/news/20091123/EraGen-Biosciences-to-have-access-to-Illuminae28099s-BeadXpress-platform.aspx>.

  • Chicago

    Illumina, Inc.. "EraGen Biosciences to have access to Illumina’s BeadXpress platform". News-Medical. https://www.news-medical.net/news/20091123/EraGen-Biosciences-to-have-access-to-Illuminae28099s-BeadXpress-platform.aspx. (accessed April 01, 2020).

  • Harvard

    Illumina, Inc.. 2019. EraGen Biosciences to have access to Illumina’s BeadXpress platform. News-Medical, viewed 01 April 2020, https://www.news-medical.net/news/20091123/EraGen-Biosciences-to-have-access-to-Illuminae28099s-BeadXpress-platform.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
HudsonAlpha buys Illumina HiSeq X Ten sequencing system